Aspirin monotherapy is as effective and safe as a regimen of rivaroxaban followed by aspirin for preventing symptomatic venous thromboembolism (VTE) after total hip or knee arthroplasty, according to findings from the EPCAT III randomized trial. The study, published in the New England Journal of Medicine, found no clinically relevant difference in bleeding events between the two groups, suggesting that a simpler, lower-cost aspirin-only strategy is a viable option for patients at standard risk for blood clots.
Comparing Aspirin and Rivaroxaban Efficacy
The EPCAT III trial, led by Sudeep Shivakumar, MD, of Dalhousie University and Nova Scotia Health Authority, followed 5,429 participants across 15 university-affiliated health centers in Canada. Researchers compared a daily 81 mg aspirin regimen against a protocol of 10 mg rivaroxaban for five days, followed by aspirin.
The primary effectiveness endpoint—the incidence of symptomatic VTE (proximal deep vein thrombosis or pulmonary embolism) over 90 days—was 0.48% for the aspirin-only group and 0.45% for the rivaroxaban-aspirin group. The risk difference of 0.02 met the trial’s noninferiority criteria. Safety data proved equally comparable: major or clinically relevant nonmajor bleeding occurred in 1.66% of the aspirin-only cohort compared to 2.04% in the rivaroxaban-aspirin group.
Navigating Risk and Patient Selection
While the trial results offer a pathway to simplify postoperative care, investigators emphasized that the findings apply primarily to patients at standard risk. The average STOP-VTE score among participants was 1.1, with only 3.4% classified as high-risk. Patients with a history of VTE, recent limb fractures, or metastatic cancer were excluded from the study.
“As such, an individualized strategy should be considered if a patient is identified as being at higher risk for VTE,” study authors cautioned.
Did you know?
The EPCAT III trial results provide a contrast to the 2022 CRISTAL study, which was halted early after interim analysis suggested higher rates of distal deep vein thrombosis in patients taking aspirin monotherapy compared to those on enoxaparin. In the EPCAT III trial, an expanded analysis including distal DVT showed no significant difference between the study groups (1.03% for aspirin vs. 0.87% for rivaroxaban-aspirin).
The Evolution of Post-Surgical Prophylaxis
Over the last decade, direct oral anticoagulants (DOACs) like rivaroxaban and apixaban have gained widespread adoption for VTE prevention following joint replacement. However, the evidence base for aspirin as a primary prophylactic agent has continued to grow. The EPCAT III findings build on the earlier EPCAT II trial, which previously demonstrated that switching from rivaroxaban to aspirin after five days was as safe and effective as continuing the DOAC alone.
By demonstrating that some patients may bypass the DOAC stage entirely, the research provides a basis for reducing both the complexity of medication management and the financial burden on patients. As healthcare systems seek to optimize value-based care, the use of inexpensive, widely available medications like aspirin for standard-risk arthroplasty cases may become a more common clinical standard.
Frequently Asked Questions
- Is aspirin as effective as rivaroxaban for everyone? The trial focused on patients at “standard risk.” Patients with elevated risk factors, such as a history of VTE or metastatic cancer, were excluded and should follow individualized plans.
- How long was the prophylaxis period? Patients received either aspirin or rivaroxaban for the first five days post-surgery, followed by 81 mg of aspirin daily for 9 additional days after knee surgery or 30 days after hip surgery.
- Did bleeding risks differ? No. The trial found no clinically meaningful difference in major or nonmajor bleeding events between the aspirin-only group and those who took rivaroxaban initially.
Are you a healthcare provider or a patient navigating post-arthroplasty recovery? Share your thoughts on these findings in the comments below, or subscribe to our newsletter for the latest updates on orthopedic research and clinical guidelines.
